Moving on to other monoclonal antibodies, an important reference is the set of CONCERT trials (CONcomitant Chemotherapy and/or EGFR inhibition with Radiation Therapy), which investigated the use of panitumumab in addition or in substitution to cisplatin-based chemotherapy and in combination with radiation, for the treatment of locally advanced SCCHN. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.